Edwards Lifesciences (NYSE:EW) Stock Rating Raised to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Edwards Lifesciences (NYSE:EW) from a hold rating to a buy rating in a research report report published on Sunday morning,Wall Street Zen reports.

Other equities research analysts also recently issued reports about the stock. Argus lifted their target price on shares of Edwards Lifesciences from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, August 21st. The Goldman Sachs Group upped their price target on shares of Edwards Lifesciences from $98.00 to $102.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Thursday, October 15th. Raymond James Financial raised their price target on shares of Edwards Lifesciences from $100.00 to $103.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Finally, TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, October 27th. Twenty-three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $108.88.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $101.91 on Friday. The stock has a 50-day moving average price of $88.92 and a two-hundred day moving average price of $85.78. Edwards Lifesciences has a 12 month low of $74.66 and a 12 month high of $104.17. The company has a market capitalization of $58.60 billion, a PE ratio of 57.58, a P/E/G ratio of 2.72 and a beta of 0.85. The company has a current ratio of 4.60, a quick ratio of 3.86 and a debt-to-equity ratio of 0.05.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.06. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The company had revenue of $1.72 billion for the quarter, compared to analysts’ expectations of $1.68 billion. During the same period in the previous year, the business posted $0.67 earnings per share. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. Analysts expect that Edwards Lifesciences will post 3.02 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the transaction, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 5,045 shares of company stock valued at $451,596. 0.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in EW. Pin Oak Investment Advisors Inc. bought a new stake in shares of Edwards Lifesciences in the second quarter valued at $26,000. TrinityBridge Ltd bought a new stake in Edwards Lifesciences during the 2nd quarter worth approximately $27,000. GK Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the third quarter worth $26,000. RMG Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $26,000. Finally, Compass Financial Management LLC bought a new stake in Edwards Lifesciences during the second quarter valued at approximately $32,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported Q3 sales growth of 11.2% to $1.72 billion, with adjusted earnings and revenue beating estimates. TMTT sales rose 45.6% and TAVR sales grew 8.8%; the company raised its sales outlook and set adjusted full-year EPS guidance of $2.97–$3.05. Edwards Q3 earnings call highlights
• Positive Sentiment: PROGRESS Trial results found TAVR outperformed active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes. The findings could support earlier use of the procedure and expand Edwards’ potential market. Trial data points to earlier TAVR use
• Positive Sentiment: Analysts lifted price targets following the results: UBS raised its target to $118 and JPMorgan to $120, while Piper Sandler reaffirmed its buy-equivalent rating with a $115 target. The latest target increases and reaffirmations add to bullish sentiment. UBS reaffirms buy rating Piper Sandler keeps buy rating
• Negative Sentiment: Management has acknowledged that more competition is coming in TAVR, a potential pressure on market share and future growth, although the recent results and trial data provide positive offsets. CEO comments on TAVR competition

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery.

The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

Its structural heart portfolio includes transcatheter aortic valve replacement (TAVR) systems and therapies addressing mitral and tricuspid valve disease.